Gain Therapeutics (GANX) filed a registration statement Wednesday for the potential sale of up to $100 million of its securities from time to time in one or more offerings.

The filing covers common stock, preferred stock, warrants, debt securities, subscription rights and units.

The company plans to use the proceeds for working capital and general corporate purposes, unless specified otherwise at the time of the offerings.

Shares of Gain Therapeutics were up nearly 3% in after-hours trading.